1 2 3 4 5 6 7

читать далее ... ь, а также блокаторы гликопротеиновых IIb/IIIa рецепторов) и статины, польза которых установлена в специальных исследованиях. 1. Mack M., Brown P., Kugetmass A. et al. Current status and outcomes of coronary revascularization 1999 to 2002: 148,396 surgical and percutaneous procedures. Ann. Thorac. Surg., 2004, 77 (3), 761-766. 2. ACC/AHA Guidelines for Percutaneous Coronary Intervention (Revision of the 1993 PTCA Guidelines). Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 2001, 103, 3019-3041. 3. Suwaidi J., Salam A. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. Curr. Control. Trials Cardiovasc. Med., 2001, 2. 171-179. 4. LincoffA., Califf R , Molitemo D. et al. Complementary clinical benefits of coronary artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. N. Engl. J. Med., 1999, 341, 319-327. 5. The ESPRIT investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized, placebo-controlled trial. Lancet, 2000, 356, 2037-2044. 6. O'Shea J., Buller С., Cantor W. et al. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA, 2002, 287 (5), 618-621. 7. Kand/ari D., Hasselblad V., Tcheng J. et al. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. Am Heart J., 2004, 147 (3), 457-462. 8. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (CURE). Effects of Clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med., 2001, 345, 494-502. 9. Mehta S., Yusuf S. Peters R. et al. Effects of pretreatment with Clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet, 2001, 358, 527-533. 10. Steinhubl S., Berger P., Mann J. et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. A randomized controlled trial JAMA, 2002, 288, 2411-2420. 11. Chang S., Yazbek N.. Lakkis N. Use ofstatins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome. Catheter Cardiovasc. Interv , 2004, 62 (2). 193-197. 12. Chan A., Bhatt D., Chew D. et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intevention. Circulation, 2002, 105 (6), 691-696. 13. Serruys P., de Feyter P , Macaya C. et al for Lescol Intervention Prevention Study (LIPS) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002, 287 (24), 3259-3261. 14. Kernis S., Hariai К., Stone G et al. Does beta-blocker therapy improve clinical outcomes of acute Источник: Клиническая фармакология и терапия. 2004. №4. С. 5-10